(Q38082516)

28 August 2017

title

Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors? (English)

1 reference

28 August 2017

Yuri Tolkach

1

1 reference

28 August 2017

Steven Joniau

series ordinal

2

1 reference

28 August 2017

Hendrik Van Poppel

series ordinal

3

1 reference

28 August 2017

publication date

18 February 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

111

1 reference

28 August 2017

issue

7

1 reference

28 August 2017

page(s)

1021-1030

1 reference

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

The clinical implications of the difference between castration, gonadotrophin releasing-hormone (GnRH) antagonists and agonist treatment on the morphology and expression of GnRH receptors in the rat ventral prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Gonadotropin-releasing hormone and its receptor in normal and malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Gonadotropin-releasing hormone receptor expression in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

LHRH-conjugated lytic peptides directly target prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Prolactin and luteinizing hormone-releasing hormone receptors in human benign prostatic hyperplasia and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

The partial purification and characterization of GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Expression of GnRH type II is regulated by the androgen receptor in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Silencing of the GnRH type 1 receptor blocks the antiproliferative effect of the GnRH agonist, leuprolide, on the androgen-independent prostate cancer cell line DU145.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Immunocytochemical localisation of follicle stimulating hormone (FSH) in normal, benign and malignant human prostates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Prostate—an extrapituitary source of follicle-stimulating hormone (FSH): Occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2013.11796.X

10.1111/J.1464-410X.2013.11796.X

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference